Keros Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Keros Therapeutics
KROS Stock  USD 57.74  0.81  1.38%   
Keros Therapeutics financial statements provide useful quarterly and yearly information to potential Keros Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Keros Therapeutics financial statements helps investors assess Keros Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Keros Therapeutics' valuation are summarized below:
Gross Profit
-87.3 M
Market Capitalization
2.4 B
Enterprise Value Revenue
2.8 K
Revenue
651 K
Earnings Share
(5.22)
There are over one hundred nineteen available fundamental ratios for Keros Therapeutics, which can be analyzed over time and compared to other ratios. All traders should check Keros Therapeutics' last-minute fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 693.2 M in 2024. Enterprise Value is likely to drop to about 545.9 M in 2024

Keros Therapeutics Total Revenue

143,450

Check Keros Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Keros Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 0.0 or Interest Income of 3.1 M, as well as many indicators such as Price To Sales Ratio of 7.3 K, Dividend Yield of 0.0 or PTB Ratio of 3.35. Keros financial statements analysis is a perfect complement when working with Keros Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Keros Therapeutics Correlation against competitors.
For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.

Keros Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets227.3 M370 M112.4 M
Slightly volatile
Short and Long Term Debt Total15.2 M14.4 M4.9 M
Slightly volatile
Other Current Liabilities18.8 M17.9 M4.4 M
Slightly volatile
Total Current Liabilities13.9 M24.4 M12.1 M
Slightly volatile
Total Stockholder Equity207.7 M332.2 M96.2 M
Slightly volatile
Other Liabilities93.9 K55.8 K132.9 K
Slightly volatile
Property Plant And Equipment Net20.4 M19.5 M5.1 M
Slightly volatile
Current Deferred Revenue20.8 M19.8 M10.8 M
Slightly volatile
Accounts Payable3.1 M5.5 M1.6 M
Slightly volatile
Cash208.3 M331.1 M102.1 M
Slightly volatile
Non Current Assets Total23.9 M22.7 M6.1 M
Slightly volatile
Non Currrent Assets Other2.2 M2.1 M743 K
Slightly volatile
Other Assets4.2 M4 M1.2 M
Slightly volatile
Long Term Debt4 M5.7 M3.4 M
Slightly volatile
Cash And Short Term Investments208.3 M331.1 M102.1 M
Slightly volatile
Common Stock Total Equity2 K2.3 K1.4 K
Slightly volatile
Common Stock Shares Outstanding20.4 M29.4 M13.5 M
Slightly volatile
Long Term Debt Total4 M5.7 M3.4 M
Slightly volatile
Liabilities And Stockholders Equity227.3 M370 M112.4 M
Slightly volatile
Non Current Liabilities Total14.1 M13.4 M4.7 M
Slightly volatile
Capital Surpluse610.8 M581.7 M159.6 M
Slightly volatile
Capital Lease Obligations15.2 M14.4 M3.5 M
Slightly volatile
Other Current Assets15.8 M15.1 M2.8 M
Slightly volatile
Other Stockholder Equity404.8 M713.6 M174.4 M
Slightly volatile
Total Liabilities19.6 M37.8 M16.3 M
Slightly volatile
Property Plant And Equipment Gross22.2 M21.2 M5.3 M
Slightly volatile
Total Current Assets217.6 M347.3 M107.2 M
Slightly volatile
Capital Stock2.9 K3 K12 M
Slightly volatile
Non Current Liabilities Other15.5 M14.7 M4.4 M
Slightly volatile
Net Working Capital203.6 M322.9 M95.1 M
Slightly volatile
Short Term Debt921.6 K1 M485.1 K
Slightly volatile
Common Stock2.2 K3 K1.5 K
Slightly volatile
Property Plant Equipment1.8 M2.3 M1.6 M
Slightly volatile
Net Receivables1 M1.1 M2 M
Pretty Stable
Deferred Long Term Liabilities320 K360 K392 K
Slightly volatile

Keros Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income3.1 M3 M1.1 M
Slightly volatile
Depreciation And Amortization857.1 K815 K530.9 K
Slightly volatile
Selling General Administrative18.6 M34.8 M8.8 M
Slightly volatile
Total Revenue143.4 K151 K9.5 M
Pretty Stable
Other Operating Expenses178.6 M170.1 M46.6 M
Slightly volatile
Research Development142 M135.3 M37.5 M
Slightly volatile
Cost Of Revenue774.2 K815 K7.5 M
Slightly volatile
Total Operating Expenses178.6 M170.1 M46.6 M
Slightly volatile
Reconciled Depreciation459.4 K815 K279.3 K
Slightly volatile

Keros Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock101.1 M138.4 M52.7 M
Slightly volatile
Stock Based Compensation30.2 M28.8 M6.3 M
Slightly volatile
Begin Period Cash Flow149.1 M280.4 M66.9 M
Slightly volatile
Other Cashflows From Financing Activities3 M3.1 M10.9 M
Pretty Stable
Depreciation459.4 K815 K279.3 K
Slightly volatile
Other Non Cash Items1 M1.6 M695.4 K
Slightly volatile
Capital Expenditures2.6 M2.5 M655.6 K
Slightly volatile
Issuance Of Capital Stock126.6 M175.8 M60.6 M
Slightly volatile
Total Cash From Financing Activities116.5 M179 M56.2 M
Slightly volatile
End Period Cash Flow209.1 M332.4 M102.5 M
Slightly volatile
Change To Netincome22.6 M21.5 M5.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.3 K7 K1.5 K
Slightly volatile
PTB Ratio3.353.524311.9716
Slightly volatile
Days Sales Outstanding2.5 K2.4 K566
Slightly volatile
Book Value Per Share6.8811.28174.6662
Slightly volatile
Stock Based Compensation To Revenue18017136.2119
Slightly volatile
Capex To Depreciation1.513.02331.6139
Slightly volatile
PB Ratio3.353.524311.9716
Slightly volatile
EV To Sales5.3 K5.1 K1.1 K
Slightly volatile
Payables Turnover0.140.149512.7496
Slightly volatile
Sales General And Administrative To Revenue21820844.0114
Slightly volatile
Research And Ddevelopement To Revenue846806171
Slightly volatile
Capex To Revenue15.4214.693.1168
Slightly volatile
Cash Per Share7.0311.24555.3796
Slightly volatile
Days Payables Outstanding2.6 K2.4 K583
Slightly volatile
Net Debt To EBITDA1.982.081118.5583
Slightly volatile
Current Ratio12.5614.24918.3064
Slightly volatile
Tangible Book Value Per Share6.8811.28174.6662
Slightly volatile
Receivables Turnover0.150.167.4094
Slightly volatile
Graham Number38.1336.315412.5542
Slightly volatile
Shareholders Equity Per Share6.8811.28174.6662
Slightly volatile
Debt To Equity0.04520.0430.0119
Slightly volatile
Capex Per Share0.08790.08370.0356
Slightly volatile
Graham Net Net6.389.98924.1314
Slightly volatile
Revenue Per Share0.00560.00590.8665
Slightly volatile
Interest Debt Per Share0.50.470.1073
Slightly volatile
Debt To Assets0.04090.03890.0109
Slightly volatile
Operating Cycle2.5 K2.4 K743
Slightly volatile
Price Book Value Ratio3.353.524311.9716
Slightly volatile
Days Of Payables Outstanding2.6 K2.4 K583
Slightly volatile
Ebt Per Ebit0.740.90030.7627
Slightly volatile
Company Equity Multiplier1.551.11381.8131
Slightly volatile
Long Term Debt To Capitalization0.04170.03970.0098
Slightly volatile
Total Debt To Capitalization0.04310.04110.0115
Slightly volatile
Debt Equity Ratio0.04520.0430.0119
Slightly volatile
Quick Ratio12.4914.24918.263
Slightly volatile
Net Income Per E B T1.161.151.1659
Slightly volatile
Cash Ratio12.0613.58667.9171
Slightly volatile
Days Of Sales Outstanding2.5 K2.4 K566
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.811.01980.9741
Very volatile
Price To Book Ratio3.353.524311.9716
Slightly volatile
Fixed Asset Turnover0.00850.00895.8137
Slightly volatile
Debt Ratio0.04090.03890.0109
Slightly volatile
Price Sales Ratio7.3 K7 K1.5 K
Slightly volatile
Asset Turnover4.0E-45.0E-40.2903
Slightly volatile
Price Fair Value3.353.524311.9716
Slightly volatile

Keros Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap693.2 M1.2 B487.9 M
Slightly volatile
Enterprise Value545.9 M854.1 M392.5 M
Slightly volatile

Keros Fundamental Market Drivers

Cash And Short Term Investments331.1 M

Keros Upcoming Events

1st of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Keros Therapeutics Financial Statements

Keros Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Keros Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Keros Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Keros Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue19.8 M20.8 M
Total Revenue151 K143.4 K
Cost Of Revenue815 K774.2 K
Stock Based Compensation To Revenue 171.44  180.01 
Sales General And Administrative To Revenue 207.62  218.00 
Research And Ddevelopement To Revenue 806.17  846.48 
Capex To Revenue 14.69  15.42 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue-1.3 K-1.2 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY